U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06945406) titled 'A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes' on April 18.
Brief Summary: The purpose of this study is to evaluate how well LY4057996 is tolerated and what side effects may occur in healthy participants and participants with Type 1 and Type 2 Diabetes. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4057996 gets into the bloodstream and how long it takes the body to eliminate it.
The study will last 11 weeks for Part A1-A2, 4 weeks for A3-A5, 5 weeks for ...